Authors: Jeffrey A. Toretsky, Hayriye V. Erkizan, Yali Kong, Julie S. Barber-Rotenberg, Milton L. Brown, and Aykut ren, of Georgetown Lombardi Comprehensive Cancer Center; Melinda Merchant, of Pediatric Oncology Branch, National Institutes of Health
To be presented: Tuesday, April 20, 9:00 am -12:00 pm; Exhibit Hall A-C, Poster Section 18; Board 12
EWS-FLI1 is regulated by acetylation (Abstract # 3897)
EMBARGO: Tuesday, April 20, 2010; 2:00 pm ET
Author's summary: "EWS-FLI1 is a protein specific to Ewing's Sarcoma Family of Tumors (ESFT). EWS-FLI1 is a transcription factor and thereby a central regulator of ESFT cell survival and tumor growth. The mechanisms controlling its function and stability are not well understood. We show, for the first time, that EWS-FLI1 is modified by acetylation, a process that can in fact regulate both stability and function of proteins. Drugs called Histone Deacetylase Inhibitors (HDI) inhibit the reverse process, the deacetylation of proteins, and are promising in the treatment of a variety of cancers. HDI act mainly (but not solely) by deacetylating histone protein, and are very active in inducing cell death of ESFT cells. We investigate how acetylation regulates EWS-FLI1 and the possibility of EWS-FLI1 being a specific target for the activity of HDI in ESFT cells." Silke Schlottmann
Authors: Silke Schlottmann, Hayriye V. Erkizan, Julie Barber-Rotenberg, Aykut Uren, Maria L. Avantaggiati, and Jeffrey A. Toretsky. Georgetown Lombardi Comp. Cancer Ctr.
|Contact: Karen Mallet|
Georgetown University Medical Center